Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study

[1]  Y. Iwatani,et al.  Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto's disease and the intractability of Graves' disease, respectively. , 2020, Endocrine journal.

[2]  Rui-ping Liu,et al.  Association between vascular endothelial growth factor receptor 2 rs11941492 C/T polymorphism and Chinese Han patients in rheumatoid arthritis , 2019, Medicine.

[3]  J. Todd,et al.  Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic β-Cells , 2019, Diabetes Care.

[4]  M. Mańczak,et al.  KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis , 2019, Biomolecules.

[5]  J. Krischer,et al.  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. , 2019, The New England journal of medicine.

[6]  Alexander S. Bayden,et al.  Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides , 2019, Investigational New Drugs.

[7]  E. Vicaut,et al.  Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial , 2018, Annals of the rheumatic diseases.

[8]  D. Klatzmann,et al.  Regulatory T cells in the treatment of disease , 2018, Nature Reviews Drug Discovery.

[9]  J. Todd,et al.  The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. , 2018, JCI insight.

[10]  R. Tibshirani,et al.  An immune clock of human pregnancy , 2017, Science Immunology.

[11]  S. Saydah,et al.  Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012 , 2017, The New England journal of medicine.

[12]  Adrian P Mander,et al.  Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial , 2016, PLoS medicine.

[13]  A. Annoni,et al.  Insulin B chain 9–23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs , 2015, Science Translational Medicine.

[14]  D. Klatzmann,et al.  The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases , 2015, Nature Reviews Immunology.

[15]  D. Klatzmann,et al.  Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. , 2015, Journal of autoimmunity.

[16]  D. Klatzmann,et al.  Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes , 2015, Diabetes.

[17]  D. Klatzmann,et al.  Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes , 2014, Current Diabetes Reports.

[18]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[19]  J. Melenhorst,et al.  Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity , 2014, Clinical Cancer Research.

[20]  Darrell M. Wilson,et al.  B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results , 2014, Diabetes Care.

[21]  D. Klatzmann,et al.  Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. , 2013, The lancet. Diabetes & endocrinology.

[22]  O. Boyman,et al.  Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes , 2013, Diabetes.

[23]  M. Atkinson,et al.  Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials , 2012, Diabetes.

[24]  J. Bluestone,et al.  Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function , 2012, Diabetes.

[25]  W. Młynarski,et al.  Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children , 2012, Diabetes Care.

[26]  F. Carrat,et al.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.

[27]  G. Eisenbarth,et al.  Immune intervention in type 1 diabetes. , 2011, Seminars in immunology.

[28]  W. Jędrzejczak,et al.  Potential role of immunoablation and hematopoietic cell transplantation in the treatment of early diabetes type 1. , 2010, Annals of transplantation.

[29]  D. Sobel,et al.  Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus , 2010, Acta Diabetologica.

[30]  K. Cerosaletti,et al.  Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects , 2009, Diabetes.

[31]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[32]  J. Bluestone,et al.  CD3-specific antibodies: a portal to the treatment of autoimmunity , 2007, Nature Reviews Immunology.

[33]  J. Ritz,et al.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.

[34]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[35]  A. Shapiro,et al.  Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. , 2002, Diabetes.

[36]  A. Barlow,et al.  Anti-CD2 monoclonal antibodies prevent spontaneous and adoptive transfer of diabetes in the BB/Wor rat. , 1992, The American journal of pathology.

[37]  R. Puri,et al.  Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Friedman.  Multivariate adaptive regression splines , 1990 .

[39]  Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin Secretion , 1988, Diabetes.

[40]  M. Mihatsch,et al.  Factors associated with early remission of type I diabetes in children treated with cyclosporine. , 1988, The New England journal of medicine.

[41]  G. E. Noether,et al.  Sample Size Determination for Some Common Nonparametric Tests , 1987 .

[42]  G. Karsenty,et al.  CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET Results of a Multicentre Double-blind Trial , 1986, The Lancet.

[43]  A. Laupacis,et al.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. , 1984, Science.

[44]  E. Mayer-Davis,et al.  Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. , 2017, The New England journal of medicine.

[45]  Shimon Sakaguchi,et al.  Regulatory T cells exert checks and balances on self tolerance and autoimmunity , 2010, Nature Immunology.